pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

668 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1172Endpoints887BioPharma Dive342BioSpace307Fierce Biotech290onclive165raps104globenewswire health73
therapy area
allOncology7564Rare Disease1864Cardiology1738Immunology1478Hematology1318Vaccines1197Pulmonology1147Psychiatry & CNS866
  • Predicting consequences of new hepatitis B vaccine recs
    New data on public trust in science, AI and mental health, and other news from Morning Rounds
    STAT · 4mo ago↗ source
  • Opinion: It’s time to seize the rare bipartisan opening to address microplastics
    “This could be the start of serious action on microplastics. Or it could end up as a headline with little behind it,” write Tim Ryan and Justin Zorn.
    STAT · 4mo ago↗ source
  • STAT+: Erasca touts strong, though preliminary, results in trial of pancreatic and lung cancer therapy
    The drugmaker Erasca said results on its experimental pill in a trial of pancreatic cancer and non-small cell lung cancer exceeded its expectations.
    STAT · 4mo ago↗ source
← prev
page 27 of 27
next →
fda recalls67
fda medwatch60
fda press38
Ophthalmology494
Pain478
Endocrinology & Metabolism471
Infectious Disease444
  • STAT+: Astellas retries XLMTM gene therapy after deaths
    Veradermics' hair loss pill late-stage trial success, FDA fast-tracks reviews for psychedelics, and more biotech news
    STAT · 4mo ago↗ source
  • STAT+: Pharmalittle: We’re reading about a Lilly deal, an Intellia CRISPR rare-disease treatment, and more
    Intellia disclosed that a single dose of its gene editing treatment dramatically reduced swelling attacks in patients with hereditary angioedema
    STAT · 4mo ago↗ source
  • Intellia CRISPR drug succeeds in late-stage study against rare swelling disorder
    The findings position Intellia to bring to market the first “in vivo” gene editing medicine, though the therapy’s commercial potential remains the source of intense investor debate.
    BioPharma Dive · 4mo ago↗ source
  • STAT+: Intellia says CRISPR-based treatment for rare disease reduced swelling attacks in pivotal trial
    With good results from Intellia, the CRISPR field faces the question: How attractive will the one-and-done approach be to patients and doctors?
    STAT · 4mo ago↗ source
  • STAT+: Zap in a cap: How one neurotech startup is using a hat to treat depression
    FDA approved a request from Motif Neurotech, to start an initial feasibility trial to test a brain implant to treat depression.
    STAT · 4mo ago↗ source
  • International childhood vaccine campaign grows
    In today's Morning Rounds newsletter, a new era in GOP drug policy, an international childhood vaccine campaign grows, and more.
    STAT · 4mo ago↗ source
  • Opinion: I started medical school at 69 and will begin residency at 72. Here’s what I learned
    Starting residency at 72 isn’t for the faint of heart. But that’s what Dawn Zuidegeest-Craft is doing.
    STAT · 4mo ago↗ source
  • STAT+: Trump celebrates closing first round of drug pricing deals, promises more ahead
    A deal with Regeneron was the last of 17 initially sought by the White House.
    STAT · 4mo ago↗ source
  • FDA approves Regeneron’s hearing loss gene therapy
    Otarmeni, now cleared to treat a rare, inherited kind of hearing loss, is the first gene therapy cleared under the FDA’s “national priority” voucher program and will be offered to eligible patients…
    BioPharma Dive · 4mo ago↗ source
  • FDA approves Regeneron's hearing loss gene therapy Otarmeni
    Regeneron has won the first-ever FDA approval for a gene therapy to treat a rare type of inherited hearing loss, and the company plans to offer the treatment for free in the US, though that ...
    Endpoints · 4mo ago↗ source
  • Heart’s beat may help it beat cancer, mouse research suggests
    The constant pressure that the heart is under from beating thousands of times a day may create an environment hostile to cancers
    STAT · 4mo ago↗ source
  • STAT+: Legislatures in Colorado and Virginia resist moves to constrain drug affordability boards
    Legislators in two states are resisting efforts to restrict prescription drug affordability boards.
    STAT · 4mo ago↗ source
  • Sanofi posts upbeat sales as R&D pressure builds
    A string of research setbacks have left the pharmaceutical giant at a crossroads just as a new CEO is set to take over. But positive first-quarter earnings provided the company with a needed boost.
    BioPharma Dive · 4mo ago↗ source
  • Fierce Biotech Layoff Tracker 2026: Novartis nixes Swiss site; TScan telegraphs 75% headcount drop
    As always, if you know of layoffs occurring at a biotech, please reach out to the Fierce Biotech editorial team.
    Fierce Biotech · 8mo ago↗ source
  • Fierce Biotech Fundraising Tracker '26: Brainchild conjures $116M; Moonwalk steps into $70M
    The Fierce Biotech Fundraising Tracker records venture capital rounds of $50 million or more secured by biotechs.
    Fierce Biotech · 8mo ago↗ source